HealthRX.com · Printable cost worksheet
NAD+ option cost-per-day worksheet: fill in today's prices yourself
Prices change and this page cannot date them, so the worksheet leaves them to you: record what you were quoted, work out the cost per day, and set it beside what each option's best-known trial actually showed.
Price each option yourself
Cost per day = price ÷ days the pack lasts at the amount you would take.
| Option and brand | Price paid or quoted | Date and seller | Units per pack | Units per day | Days the pack lasts | Cost per day |
|---|---|---|---|---|---|---|
What the best-known trial for each option showed
- NMN: in a 10-week trial in postmenopausal women with prediabetes, muscle insulin sensitivity improved.[1]
- NR: in a 12-week trial in men with obesity, insulin sensitivity did not improve.[2]
- Nicotinamide: in 386 adults with past skin cancers, new non-melanoma skin cancers were 23% lower at 12 months.[3]
- Nicotinamide: in 158 organ-transplant recipients, new skin cancers were not reduced at 12 months.[4]
- Niacin with laropiprant, added to statins: no fewer major vascular events over a median 3.9 years, and more serious adverse events.[5]
- Since September 29, 2025, FDA's position is that NMN is not excluded from the dietary supplement definition.[6]
- Compounded drugs, including compounded infusions, are not FDA-approved.[7]
Your comparison
Monthly amount you are willing to spend
What result would justify the costfor example a lab value you and your clinician agree on
Review date
Before paying for any option
- The label states the ingredient and the amount per serving
- An independent lab's certificate of analysis is available for the lot
- You checked FDA's current position on the ingredient and wrote down the date
- Your clinician knows which option you chose
- You agreed a marker to check and a date to check it
Sources for the facts on this sheet
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021. PMID 33888596. https://pubmed.ncbi.nlm.nih.gov/33888596/
- Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018. PMID 29992272. https://pubmed.ncbi.nlm.nih.gov/29992272/
- Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015. PMID 26488693. https://pubmed.ncbi.nlm.nih.gov/26488693/
- Allen NC, Martin AJ, Snaidr VA, et al. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. N Engl J Med 2023. PMID 36856616. https://pubmed.ncbi.nlm.nih.gov/36856616/
- Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014. PMID 25014686. https://pubmed.ncbi.nlm.nih.gov/25014686/
- U.S. Food and Drug Administration. FDA letter to Inner Mongolia Kingdomway Pharmaceutical Limited regarding NDIN 1259, beta-nicotinamide mononucleotide (NMN). Accessed 2026-10-19. https://downloads.regulations.gov/FDA-2022-S-0023-0069/attachment_1.pdf
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Accessed 2026-10-19. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.